CAMBRIDGE, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset
clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for
multidrug-resistant bacterial infections, announced today that Ankit Mahadevia, M.D., President and Chief Executive Officer of
Spero Therapeutics, will provide a corporate update at the Jefferies 2018 Healthcare Conference on Wednesday, June 6th, 2018 at
4:30 PM ET in New York, New York.
The live presentation may be accessed through Spero Therapeutics’ website (www.sperotherapeutics.com) on the “Events and Presentations” page under the “Investors and
Media” tab. A replay of the presentation will be archived on the website for 90 days following the conclusion of the
event.
About Spero
Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying,
developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections.
The Company’s lead product candidate, SPR994, is designed to be the first broad-spectrum oral carbapenem-class
antibiotic for use in adults to treat MDR Gram-negative infections.
The Company also has a platform technology known as its Potentiator Platform that it believes will enable it to
develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against
Gram-negative bacteria. The Company’s lead product candidates generated from its Potentiator Platform are two intravenous, or
IV,-administered agents, SPR741 and SPR206, designed to treat MDR Gram-negative infections in the hospital setting.
Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary
non-tuberculous mycobacterial (NTM) infection.
For more information, visit https://sperotherapeutics.com.
Forward Looking Statements
This press release may contain forward-looking statements. These statements include, but are not limited
to, statements about the initiation, timing, progress and results of the Company’s preclinical studies and clinical trials and the
Company’s research and development programs, including statements regarding management’s assessment of the results of such
preclinical studies and clinical trials, the timing of clinical data, the Company’s cash forecast and anticipated expenses and the
sufficiency of the Company’s cash resources. In some cases, forward-looking statements can be identified by terms such as
“may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results
may differ materially from those indicated by such forward-looking statements as a result of various important factors, including
whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical
trials; whether the Company’s product candidates will advance through the preclinical development and clinical trial process on a
timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food
and Drug Administration or equivalent foreign regulatory agencies; whether the Company’s cash resources will be sufficient to
fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set
forth in filings that we periodically make with the U.S. Securities Exchange Commission. The forward-looking statements
included in this press release represent the Company’s views as of the date of this press release. The Company anticipates
that subsequent events and developments will cause its views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of
this press release.
Spero Investor Contact:
Sharon Klahre
Director, Investor Relations
857-242-1547
IR@sperotherapeutics.com
![Primary Logo](https://resource.globenewswire.com/Resource/Download/f9b7b81c-0c18-4d60-ae5e-ef950e9ff20b?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzI5NjkyMg==)